Information Provided By: 
Fly News Breaks for January 18, 2017
JAZZ
Jan 18, 2017 | 08:52 EDT
After the FDA announced yesterday that it approved a generic version of Xyrem with a REMS program, but also granted Jazz Pharmaceuticals' citizen petition refusing a carve-out for a generic Xyrem, Stifel analyst Annabel Samimy equated this to news that the FDA "essentially approved a [generic] that would immediately infringe on the multiple early formulation patents." The analyst, who thinks Jazz remains in the same position, if not a better one, to protect its Xyrem franchise, keeps a Buy rating and $200 price target on the stock.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
